BeyondSpring Inc.
NASDAQ: BYSI0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Lan Huang
- Employees
- 40
- Headquarters
- Florham Park, United States
- IPO year
- 2017
- Market cap
- $67.6M
- Website
- https://www.beyondspringpharma.com
Loading BYSI…
Loading profile data…Frequently asked questions about BYSI
What does BeyondSpring Inc. (BYSI) do?
BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. Its flagship product is Plinabulin, a selective immune-modulating and microtubule-binding agent. Plinabulin has successfully advanced through Phase III clinical trials for two distinct applications: the prevention of chemotherapy-induce...
Where does BYSI trade?
BeyondSpring Inc. (BYSI) trades on the NASDAQ Capital Market.
What sector is BYSI in?
BeyondSpring Inc. (BYSI) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of BeyondSpring Inc.?
Lan Huang is the chief executive officer of BeyondSpring Inc. (BYSI).
Where is BeyondSpring Inc. headquartered?
BeyondSpring Inc. is headquartered in United States.
Does BYSI pay a dividend?
BeyondSpring Inc. (BYSI) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did BYSI go public?
BeyondSpring Inc. (BYSI) completed its initial public offering in 2017.